Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Radiosensitizer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Radiosensitizer. Displaying page 1 of 1.
    EudraCT Number: 2012-000528-17 Sponsor Protocol Number: IAEA-HypoX Start Date*: 2012-06-05
    Sponsor Name:Department of Experimental Clinical Oncology
    Full Title: A randomized multicenter study of accelerated fractionated radiotherapy with or without the hypoxic radiosensitizer nimorazole in the treatment of squamous cell carcinoma of the head and neck
    Medical condition: Squamous Cell Carcinoma of the Head and Neck region
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SI (Ongoing) EE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002441-12 Sponsor Protocol Number: 1219 Start Date*: 2013-12-16
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: A blind randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic radiosensitizer nimorazole (Nimoral), using a 15 gene signature for hypoxia in the tr...
    Medical condition: Squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-001356-37 Sponsor Protocol Number: NSGO-CC-0304 Start Date*: 2004-09-10
    Sponsor Name:Nordic Society for Gynecological Cancer
    Full Title: Phase I-II-III studies of Cisplatin and Combretastatin (CA4P) in recurrent or advanced servical cancer
    Medical condition: Metastatic or recurrent cervical cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002742-11 Sponsor Protocol Number: ML20005 Start Date*: 2007-04-18
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: MULTICENTER PHASE II TRIAL OF TARCEVA COMBINED WITH FIXED DOSE-RATE GEMCITABINE INFUSION AS FIRST LINE TREATMENT OF ADVANCED, UNRESECTABLE PANCREATIC CANCER
    Medical condition: Advanced pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033633 Pancreatic neoplasms malignant (excl islet cell and carcinoid) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004637-16 Sponsor Protocol Number: SLAP Start Date*: 2009-04-28
    Sponsor Name:GISCAD
    Full Title: Folfiri as Second-Line chemotherapy for Advanced Pancreatic cancer: a GISCAD Phase II study
    Medical condition: Subjects enrolled in this study must have histologically confirmed locally advanced or metastatic pancreatic adenocarcinoma. They must have been received a first-line chemotherapy (one line only) w...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10013250 Disorder pancreas LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004572-34 Sponsor Protocol Number: MM-141-07-02-02 Start Date*: 2016-09-16
    Sponsor Name:Merrimack Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 plus Nab-paclitaxel and Gemcitabine versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
    Medical condition: Patients with metastatic adenocarcinoma of the pancreas who have not received prior therapy for their metastatic disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-000790-23 Sponsor Protocol Number: AN2025H0301 Start Date*: 2021-09-27
    Sponsor Name:Adlai Nortye USA Inc.
    Full Title: The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Medical condition: Head and Neck Squamous Cell Carcinoma (HNSCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Ongoing) HU (Ongoing) BE (Ongoing) IT (Ongoing) ES (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000640-10 Sponsor Protocol Number: 2012/VCC/0009 Start Date*: 2012-12-13
    Sponsor Name:Velindre NHS Trust
    Full Title: A randomised Phase II study of two pre-operative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carbopla...
    Medical condition: Histologically confirmed operable oesophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10056104 Squamous cell carcinoma of oesophagus LLT
    14.1 100000004864 10056092 Adenocarcinoma of oesophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001841-34 Sponsor Protocol Number: PLUTO2011 Start Date*: 2012-01-12
    Sponsor Name:NHS Greater Glasgow Health Board [...]
    1. NHS Greater Glasgow Health Board
    2. University of Glasgow
    Full Title: A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium.
    Medical condition: Relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044426 Transitional cell carcinoma urethra LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044420 Transitional cell carcinoma of the bladder stage unspecified LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044407 Transitional cell cancer of the renal pelvis and ureter PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003583-40 Sponsor Protocol Number: MS200647_0017 Start Date*: 2020-07-07
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Contai...
    Medical condition: Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Ongoing) HU (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000236-27 Sponsor Protocol Number: VEG105281 Start Date*: 2006-12-15
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Montherapy and Lapatinib Monotherapy in Subjects with FI...
    Medical condition: Patients with FIGO Stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) FR (Completed) EE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:57:21 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA